Jun 2026 (Q1 FY27) — Aug 6, 2026
STERIS plc Q1 FY27 — Strong Organic Growth and Major Investment in Formulated Chemistry
Read the full callSTERIS (STE) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
STERIS earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,493 | +7.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 19.1 | +1.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 200 | +12.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
18 of 21 judged targets kept · 18 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY27 quarterly dividend increase | increase the dividend (no specific amount given) | Mar 2026 | We also announced our 21st consecutive year of dividend increases last week with a $0.06 increase to $0.69 per quarter as we continue to prioritize dividend growth. | Achieved |
| Full-year capital expenditures | $375 million | Mar 2026 | As a result, CapEx is now anticipated to be approximately $450 million in fiscal 2027. | Revised Down |
| Full-year adjusted effective tax rate | approximately 23.5% | Mar 2025 | For the full year fiscal 2026, our adjusted effective tax rate was 24.4%, an increase of 130 basis points from fiscal 2025. | Missed |
3 of STERIS plc's 39 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 36 more targets are in the full ledger.
Claimed
- Constant currency organic revenue grew 6% in Q1 FY27, driven by volume and 190 basis points of price.
- Adjusted EPS increased 11% to $2.59 in Q1 FY27, exceeding tax expense increases.
- Healthcare segment's service revenue grew 10% and consumables grew 9% in Q1 FY27.
- Gross margin improved by 70 basis points to 46% in Q1 FY27, driven by price and productivity.
- EBIT margin increased 100 basis points to 23.8% of revenue in Q1 FY27.
Qualified
- Free cash flow decreased to $279.6 million in Q1 FY27 from $326.5 million in the prior year, primarily due to lower working capital contribution.
- AST segment's EBIT margins decreased 60 basis points to 48% in Q1 FY27 due to increased depreciation and slightly lower productivity.
- Life Sciences segment's margins decreased 140 basis points to 42.1% in Q1 FY27, impacted by unfavorable productivity and inflation.
- Gross tariff costs, excluding refunds, were $14 million in Q1 FY27, up from $12 million in the prior year.
Price
$221.97 −0.31% · −$0.69
Performance −7.6% 1Y
1Y: $240.21 on 17 Oct 2025 → $221.97. High $268.65 (16 Jan 2026), low $199.4 (17 Jun 2026).
- Previous close
- $222.66
- 52-week range
- $199.4 – $268.65
- One year
- −8.36%
Overview
- Symbol
- STE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
18 of 21 judged targets kept · 18 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY27 quarterly dividend increase | increase the dividend (no specific amount given) | Mar 2026 | We also announced our 21st consecutive year of dividend increases last week with a $0.06 increase to $0.69 per quarter as we continue to prioritize dividend growth. | Achieved |
| Full-year capital expenditures | $375 million | Mar 2026 | As a result, CapEx is now anticipated to be approximately $450 million in fiscal 2027. | Revised Down |
| Full-year adjusted effective tax rate | approximately 23.5% | Mar 2025 | For the full year fiscal 2026, our adjusted effective tax rate was 24.4%, an increase of 130 basis points from fiscal 2025. | Missed |
Claimed
- Constant currency organic revenue grew 6% in Q1 FY27, driven by volume and 190 basis points of price.
- Adjusted EPS increased 11% to $2.59 in Q1 FY27, exceeding tax expense increases.
- Healthcare segment's service revenue grew 10% and consumables grew 9% in Q1 FY27.
- Gross margin improved by 70 basis points to 46% in Q1 FY27, driven by price and productivity.
- EBIT margin increased 100 basis points to 23.8% of revenue in Q1 FY27.
Qualified
- Free cash flow decreased to $279.6 million in Q1 FY27 from $326.5 million in the prior year, primarily due to lower working capital contribution.
- AST segment's EBIT margins decreased 60 basis points to 48% in Q1 FY27 due to increased depreciation and slightly lower productivity.
- Life Sciences segment's margins decreased 140 basis points to 42.1% in Q1 FY27, impacted by unfavorable productivity and inflation.
- Gross tariff costs, excluding refunds, were $14 million in Q1 FY27, up from $12 million in the prior year.
The full ledger
Open STERIS plc’s full ledger
A free account opens 5 company ledgers a month. All 39 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q4 FY26) — May 12, 2026
STERIS Q4 FY26 — Record Year with Strong Revenue and EPS Growth
Read the full callEvery analysed call
STERIS earnings calls (STE)
Financials
What the filings say
Net profit, year on year: +13% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,329 | 1,371 | 1,481 | 1,391 | 1,460 | 1,496 | 1,588 | 1,493 |
| Operating profit | 220 | 245 | 216 | 246 | 266 | 273 | 317 | 286 |
| Operating margin | 16.5% | 17.9% | 14.6% | 17.7% | 18.2% | 18.3% | 19.9% | 19.1% |
| Other income | -25 | -16 | -19 | -14 | -13 | -15 | -12 | -12 |
| Interest | 20 | 19 | 17 | 16 | 15 | 15 | 15 | 16 |
| Profit before tax | 195 | 229 | 197 | 232 | 253 | 258 | 305 | 274 |
| Tax rate | 22.3% | 24.2% | 25.6% | 23.2% | 23.9% | 24.6% | 27.6% | 26.5% |
| Net profit | 150 | 174 | 146 | 177 | 192 | 193 | 220 | 200 |
| EPS ($ per share) | 1.52 | 1.76 | — | 1.80 | 1.95 | 1.96 | — | — |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1,999 | 1,982 | 2,003 | 4,743 | 4,486 | 4,543 | 4,420 | 4,281 |
| Reserves | 1,339 | 1,659 | 1,939 | 1,999 | 1,912 | 2,088 | 2,475 | 3,016 |
| Total liabilities | 1,887 | 2,023 | 2,683 | 4,879 | 4,735 | 4,748 | 3,531 | 3,540 |
| Fixed assets | 1,032 | 1,112 | 1,235 | 1,553 | 1,633 | 1,765 | 1,957 | 2,161 |
| Total assets | 5,073 | 5,441 | 6,574 | 11,424 | 10,822 | 11,064 | 10,147 | 10,737 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 540 | 591 | 690 | 685 | 757 | 973 | 1,148 | 1,341 |
| Cash from investing | -213 | -320 | -1,154 | -667 | -383 | -887 | 389 | -512 |
| Cash from financing | -295 | -163 | 346 | 116 | -499 | -85 | -1,572 | -568 |
| Net cash flow | 19 | 99 | -99 | 128 | -140 | -1 | -35 | 268 |
| Capital expenditure | -190 | -215 | -239 | -288 | -362 | -360 | -370 | -369 |
| Free cash flow | 350 | 376 | 450 | 397 | 395 | 613 | 778 | 972 |
STE revenue by segment
| Segment | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Healthcare | — | — | — | — | — | 71% | 72% | 70% | — |
| Applied Sterilization Technologies | 19% | 19% | 19% | 20% | 19% | 19% | 18% | 20% | +5.8% |
| Life Science | — | — | — | — | 10% | 10% | — | 10% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
STE operating KPIs by quarter
| KPI | Mar 2026 Q4 FY26 | Jun 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|
| Capital equipment backlog Healthcare | <$400MCapital equipment backlog ended just under $400 million with orders up 2% in the fourth quarter.Source: earnings call transcript | $444MOrders remained solid, with 4% growth in the first quarter, and our ending backlog increased to $444 million.Source: earnings call transcript | — |
| Capital equipment backlog Life Sciences | <$100MCapital equipment backlog ended solid at just under $100 million.Source: earnings call transcript | $110MBacklog at quarter end was about flat with prior year at $110 million.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q1 FY2027 · share of revenue
- US 73% ↓ 1 pt
- Non Us 25%
- IE 2%
As STE cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
64 filings between Nov 11, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$9.83M
12 sales by 7 insiders
25% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
- 9
- Option exercise — converted options into shares
- 33
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Zangerle John Adam | — | $4.27M | Jun 15, 2026 |
| Madsen Julia | — | $1.31M | Nov 21, 2025 |
| Tamaro Renato | — | $1.30M | Nov 18, 2025 |
| Sohi Mohsen | — | $956.8K | Aug 12, 2026 |
| Carestio Daniel A | — | $946.8K | Jun 5, 2026 |
| FELDMANN CYNTHIA L | — | $734.9K | Mar 5, 2026 |
| Breeden Richard C | — | $310.3K | Jun 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Burton Karen L Sr. Vice Pres., CFO | Tax withheld | 228 | $0 |
| Aug 12, 2026 | Sohi Mohsen Director | Sale | 4,058 | $956.8K |
| Aug 12, 2026 | Sohi Mohsen Director | Option exercise | 4,058 | $349.9K |
| Jul 1, 2026 | Sohi Mohsen Director | Option exercise | 3,781 | $270.0K |
| Jul 1, 2026 | Sohi Mohsen Director | Tax withheld | 1,837 | $390.0K |
| Jun 15, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Sale 10b5-1 plan | 1,419 | $297.0K |
| Jun 5, 2026 | Carestio Daniel A President and CEO | Sale 10b5-1 plan | 1,374 | $291.3K |
| Jun 4, 2026 | Burton Karen L Sr. Vice Pres., CFO | Tax withheld | 90 | $19.1K |
| Jun 4, 2026 | Madsen Julia Sr. VP and GM, Life Sciences | Tax withheld | 195 | $41.4K |
| Jun 4, 2026 | Kohler Kenneth E SVP & GM, AST | Tax withheld | 150 | $31.8K |
| Jun 4, 2026 | Carestio Daniel A President and CEO | Sale 10b5-1 plan | 3,054 | $655.5K |
| Jun 4, 2026 | Carestio Daniel A President and CEO | Tax withheld 10b5-1 plan | 1,889 | $400.9K |
| Jun 4, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Tax withheld | 401 | $85.1K |
| Jun 4, 2026 | Tamaro Renato V.P. & Corporate Treasurer | Tax withheld | 65 | $13.8K |
| Jun 4, 2026 | Fraser Mary Clare SVP & Chief HRO | Tax withheld | 600 | $127.3K |
| Jun 3, 2026 | Carestio Daniel A President and CEO | Tax withheld | 2,619 | $550.5K |
| Jun 3, 2026 | Burton Karen L Sr. Vice Pres., CFO | Tax withheld | 190 | $39.9K |
| Jun 3, 2026 | Madsen Julia Sr. VP and GM, Life Sciences | Tax withheld | 239 | $50.2K |
| Jun 3, 2026 | Kohler Kenneth E SVP & GM, AST | Tax withheld | 184 | $38.7K |
| Jun 3, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Tax withheld | 365 | $76.7K |
| Jun 3, 2026 | Fraser Mary Clare SVP & Chief HRO | Tax withheld | 311 | $65.4K |
| Jun 3, 2026 | Tamaro Renato V.P. & Corporate Treasurer | Tax withheld | 64 | $13.5K |
| Jun 2, 2026 | Kohler Kenneth E SVP & GM, AST | Award | 2,199 | $0 |
| Jun 2, 2026 | Fraser Mary Clare SVP & Chief HRO | Tax withheld | 591 | $124.0K |
| Jun 2, 2026 | Fraser Mary Clare SVP & Chief HRO | Award | 3,009 | $0 |
| Jun 2, 2026 | Carestio Daniel A President and CEO | Tax withheld | 995 | $208.7K |
| Jun 2, 2026 | Carestio Daniel A President and CEO | Award | 23,736 | $0 |
| Jun 2, 2026 | Burton Karen L Sr. Vice Pres., CFO | Award | 5,325 | $0 |
| Jun 2, 2026 | Burton Karen L Sr. Vice Pres., CFO | Option exercise | 66 | $13.8K |
| Jun 2, 2026 | Kohler Kenneth E SVP & GM, AST | Tax withheld | 66 | $13.8K |
| Jun 2, 2026 | Breeden Richard C Director | Option exercise | 3,781 | $270.0K |
| Jun 2, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Tax withheld | 247 | $51.8K |
| Jun 2, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Award | 4,359 | $0 |
| Jun 2, 2026 | Breeden Richard C Director | Sale | 1,481 | $310.3K |
| Jun 2, 2026 | Tamaro Renato V.P. & Corporate Treasurer | Tax withheld | 41 | $8.6K |
| Jun 2, 2026 | Tamaro Renato V.P. & Corporate Treasurer | Award | 750 | $0 |
| Jun 2, 2026 | McGowan Lindsey VP, Chf. Comp. & Quality Offc. | Tax withheld | 329 | $69.0K |
| Jun 2, 2026 | McGowan Lindsey VP, Chf. Comp. & Quality Offc. | Award | 1,155 | $0 |
| Jun 2, 2026 | Majors Cary L SVP and President, Healthcare | Tax withheld | 67 | $14.1K |
| Jun 2, 2026 | Majors Cary L SVP and President, Healthcare | Award | 4,746 | $0 |
| Jun 2, 2026 | Madsen Julia Sr. VP and GM, Life Sciences | Tax withheld | 127 | $26.6K |
| Jun 2, 2026 | Madsen Julia Sr. VP and GM, Life Sciences | Award | 2,316 | $0 |
| Jun 1, 2026 | Zangerle John Adam Sr. VP, Gen Counsel, and Sec. | Tax withheld | 337 | $0 |
| Jun 1, 2026 | Tamaro Renato V.P. & Corporate Treasurer | Tax withheld | 81 | $0 |
| Jun 1, 2026 | McGowan Lindsey VP, Chf. Comp. & Quality Offc. | Tax withheld | 198 | $0 |
| Jun 1, 2026 | Majors Cary L SVP and President, Healthcare | Tax withheld | 768 | $0 |
| Jun 1, 2026 | Madsen Julia Sr. VP and GM, Life Sciences | Tax withheld | 208 | $0 |
| Jun 1, 2026 | Kohler Kenneth E SVP & GM, AST | Tax withheld | 109 | $0 |
| Jun 1, 2026 | Fraser Mary Clare SVP & Chief HRO | Tax withheld | 673 | $0 |
| Jun 1, 2026 | Carestio Daniel A President and CEO | Tax withheld | 1,254 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for STERIS plc
Free account. Everything above stays public.
Write why you follow STERIS plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading